Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Polak

Showing results (41-50 of 105) with videos related to

Pageof 11
Sort By:
International Journal of Molecular Sciences|October 14, 2022
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part IIJakub Witkowski, Sebastian Polak, Zbigniew Rogulski, et al.
The AAPS Journal|November 29, 2017
Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of CitalopramNikunjkumar Patel, Barbara Wiśniowska, Masoud Jamei, et al.
Journal of Applied Toxicology : JAT|November 17, 2017
Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical modelsBarbara Wiśniowska, Bartosz Lisowski, Magdalena Kulig, et al.
International Journal of Molecular Sciences|November 11, 2022
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part IJakub Witkowski, Sebastian Polak, Zbigniew Rogulski, et al.
Pharmaceutics|March 28, 2026
Exploring Tafamidis Effects Through PBPK-QSP ModellingSeweryn Ulaszek, Bartek Lisowski, Barbara Wiśniowska, et al.
BMC Pharmacology & Toxicology|March 11, 2016
Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsBarbara Wiśniowska, Zofia Tylutki, Gabriela Wyszogrodzka, et al.
Pharmaceutics|July 27, 2022
Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK ModelOlha Shuklinova, Przemysław Dorożyński, Piotr Kulinowski, et al.
International Journal of Molecular Sciences|February 11, 2023
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part IIIJakub Witkowski, Sebastian Polak, Dariusz Pawelec, et al.
Database : the Journal of Biological Databases and Curation|October 8, 2022
An open-access data set of pig skin anatomy and physiology for modelling purposesLaura Krumpholz, James F Clarke, Sebastian Polak, et al.
International Journal of Pharmaceutics|July 18, 2025
Physiologically based pharmacokinetic modelling of in vitro skin permeation of sunscreen actives under various experimental conditionsYuri Dancik, Yanling Zhang, Krishna C Telaprolu, et al.
Pageof 11

Showing results (41-50 of 105) with videos related to

Sort By:
Pageof 11
International Journal of Molecular Sciences|October 14, 2022
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part IIJakub Witkowski, Sebastian Polak, Zbigniew Rogulski, et al.
The AAPS Journal|November 29, 2017
Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of CitalopramNikunjkumar Patel, Barbara Wiśniowska, Masoud Jamei, et al.
Journal of Applied Toxicology : JAT|November 17, 2017
Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical modelsBarbara Wiśniowska, Bartosz Lisowski, Magdalena Kulig, et al.
International Journal of Molecular Sciences|November 11, 2022
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part IJakub Witkowski, Sebastian Polak, Zbigniew Rogulski, et al.
Pharmaceutics|March 28, 2026
Exploring Tafamidis Effects Through PBPK-QSP ModellingSeweryn Ulaszek, Bartek Lisowski, Barbara Wiśniowska, et al.
BMC Pharmacology & Toxicology|March 11, 2016
Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsBarbara Wiśniowska, Zofia Tylutki, Gabriela Wyszogrodzka, et al.
Pharmaceutics|July 27, 2022
Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK ModelOlha Shuklinova, Przemysław Dorożyński, Piotr Kulinowski, et al.
International Journal of Molecular Sciences|February 11, 2023
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part IIIJakub Witkowski, Sebastian Polak, Dariusz Pawelec, et al.
Database : the Journal of Biological Databases and Curation|October 8, 2022
An open-access data set of pig skin anatomy and physiology for modelling purposesLaura Krumpholz, James F Clarke, Sebastian Polak, et al.
International Journal of Pharmaceutics|July 18, 2025
Physiologically based pharmacokinetic modelling of in vitro skin permeation of sunscreen actives under various experimental conditionsYuri Dancik, Yanling Zhang, Krishna C Telaprolu, et al.
Pageof 11